Actelion at neutral by Merrill

Actelion was given a neutral rating and fair value estimate CHF 128 per share by Merrill Lynch analyst Erica Whittaker after the company released disappointing clinical results for clazosentan for the prevention of vasospasm following subarachnoid hemorrhage. Merrill believes there is a 30% to 40% chance that Actelion will continue development of clazosentan. Shares of the Allschwill, Switzerland-based pharmaceutical company were down CHF 17.20, or 12.54%, at CHF 120 on volume of 12,040,208 shares versus the three-month running average of 146,488 shares. (SWX: ATLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.